Reach the investors backing rounds like this
Backed by China Life Capital, Shanghai Biopharmaceutical Fund +4 more · verified emails and LinkedIn on Datapile
BioGeometry raises $100M in Series A extension for its AI drug-design models - Dealroom
BioGeometry is an AI-native biopharma company that uses generative AI to create "micro-world models" of biology for designing antibodies, vaccines, peptides, and enzymes. They pair these models with automated labs in a dry-wet feedback loop to improve the system over time. This Series A extension will fund model iteration, lab expansion, and advancing their drug pipeline.
BioGeometry raises $100M in Series A extension for its AI drug-design models Dealroom
| Oct 28, 2026 | NeuroXess | $96.6M | Series B | China |
| Oct 27, 2026 | MoSense | $10.0M | Angel-plus | China |
| Oct 16, 2026 | XHEART | $687.5M | — | China |
| Oct 16, 2026 | Shanghai Machixin Technology | $224.0M | Series A | China |
You just read who funded BioGeometry. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.